Simon Stertzer Increases BioCardia Stake with $88,064 Stock Purchase Simon Stertzer, a director at BioCardia, has expanded his holdings, purchasing shares worth $88,064. This move coincides with the company’s 20% stock surge over the past week. BioCardia is also advancing clinical trials, with Phase 3 CardiAMP results expected soon and progress in its CardiALLO therapy trials for heart failure patients.1